Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CCX 354-C · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| CCX354-C 100mg twice daily | EXPERIMENTAL | - |
| CCX354-C 200mg once daily | EXPERIMENTAL | - |
| CCX354-C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CCX-354-C | DRUG | 200mg film-coated tablets once daily for 12 weeks + Methotrexate |
| Placebo | DRUG | Placebo film-coated tablets twice daily for 12 weeks + methotrexate |
| CCX354-C | DRUG | 100mg film-coated tablets twice daily for 12 weeks + methotrexate |
| CCX 354-C | DRUG | * Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days; * Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and * Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days. |
Inclusion Criteria: 1. Male or female subjects, aged 18-75 years inclusive, with functional class I to III rheumatoid arthritis (RA) based on American College of Rheumatology (ACR) criteria for at least 3 months prior to screening; wheel-chair bound subjects or those with irreversible disease will ...
Top 20 of 31 competitors
CCX 354-C is an investigational small molecule being studied for the treatment of rheumatoid arthritis. It has been evaluated in clinical trials in patients with rheumatoid arthritis, including those partially responsive to methotrexate therapy. It is not approved for any indication and remains in clinical development.
CCX 354-C is being developed by Amgen Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol AMGN. Amgen holds the development rights for this asset.
CCX 354-C is in Phase 2 clinical development for rheumatoid arthritis. A Phase 2 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA or any regulatory agency.
CCX 354-C has been studied in two completed clinical trials: NCT01242917, a Phase 2 trial in rheumatoid arthritis patients partially responsive to methotrexate, and NCT01027728, a Phase 1 trial in rheumatoid arthritis patients. Both trials were randomized, double-blind, and placebo-controlled.
Yes, CCX 354-C and CCX-354-C refer to the same investigational drug. The hyphenated form is an alternative spelling used in some references. Both names identify the same small molecule being developed by Amgen for rheumatoid arthritis.